Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy

Infection and Immunity

Volumn 70, Issue 11, 2002, Pages 6284-6293

  Murray, Henry W ^a   Lu, Christina M ^a   Mauze, Smita ^a   Freeman, Sherry ^a   Moreira, Andre L ^a   Kaplan, Gilla ^a   Coffman, Robert L ^a  

^a Box 136 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 12; MESSENGER RNA; MONOCLONAL ANTIBODY; NITRIC OXIDE SYNTHASE; RECEPTOR ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GRANULOMA; IMMUNOTHERAPY; KNOCKOUT MOUSE; LEISHMANIA DONOVANI; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; TH1 CELL; TRANSGENIC MOUSE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIMONY; GRANULOMA; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-10; RECURRENCE;

EID: 0036839677     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.11.6284-6293.2002     Document Type: Article

References (60)

1. Asseman, C., S. Mauze, M. W. Leach, R. L. Coffman, and F. Powrie. 1999. An essential role for IL-10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190:995-1004.
2. Babaloo, Z., P. M. Kaye, and M. B. Eslami. 2001. IL-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. Trans. R. Soc. Trop. Med. Hyg. 95:1-4.
3. Badaro, R., and W. Johnson. 1993. The role of interferon-υ in the treatment of visceral and diffuse cutaneous leishmaniasis. J. Infect. Dis. 167(Suppl. 1):13-17.
4. Badaro, R., C. Nascimento, J. S. Carvalho, F. Badaro, D. Russo, J. L. Ho, S. G. Reed, and T. C. Jones. 1994. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J. Infect. Dis. 170:413-418.
5. Barcellar, O., A. D'Oliveira, S. Jeronimo, and E. M. Carvalho. 2000. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 12:1228-1231.
6. Bekker, L. G., A. L. Moreira, A. Bergtold, S. Freeman B. Ryffel, and G. Kaplan. 2000. Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent. Infect. Immun. 68:6954-6959.
7. Belkaid, Y., K. F. Hoffmann, S. Mendez, S. Kamhawi, M. C. Udey, T. A. Wynn, and D. L. Sacks. 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antiobody for sterile cure. J. Exp. Med. 194:1497-1506.
8. Bhattacharyya, S., S. Ghosh, P. L. Jhonson, S. K. Bhattacharya, and S. Majumdar. 2001. Immunomodulatory role of interleukin-10 in visceral leishmaniasis: defective activation of protein kinase C-mediated signal transduction events. Infect. Immun. 69:1499-1507.
9. Bogdan, C., Y. Vodovotz, and C. F. Nathan. 1991. Macrophage deactivation by interleukin 10. J. Exp. Med. 174:1549-1555.
10. Castro, A. G., M. Neighbors, S. D. Hurst, F. Zonin, R. A. Silva, Y-J. Liu, and A. O'Garra. 2000. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. J. Exp. Med. 192:1529-1534.
11. Cenini, P., N. Berhe A. Hailu, K. McGinnes, and D. Frommel. 1993. Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J. Infect. Dis. 168:986-993.
12. Chatelain, R., S. Mauze, and R. L. Coffman. 1999. Experimental Leishmania major infection in mice: role of IL-10. Parasite Immunol. 21:211-217.
13. Curry, A., and P. M. Kaye. 1992. Recombinant interleukin-I alpha augments granuloma formation and cytokine production but not parasite clearance in mice infected with Leishmania donovani. Infect. Immun. 60:4422-4424.
14. Deckert, M., S. Soltek, G. Geginat, S. Lutjen, M. Montesinos-Rongen, H. Hof, and D. Schluter. 2001. Endogenous interleukin-10 is required for prevention of a hyperinflammatory intracerebral immune response in Listeria monocytogenes meningoencephalitis, Infect. Immun. 69:4561-4571.
15. de Medeiros, I., A. Castelo, and R. Saloma. 1998. Presence of circulating levels of interferon-υ, interleukin-10 and tumor necrosis factor-α in patients with visceral leishmaniasis. Rev. Inst. Med. Trop. S. Paulo 40:31-34.
16. Engwerda, C. R., S. C. Smelt, and P. M. Kaye. 1996. An in vivo analysis of cytokine production during Leishmania donovani infection in scid mice. Exp. Parasitol. 84:195-202.
17. Engwerda, C. R., M. L. Murphy, S. E. Cotterell, S. C. Smelt, and P. M. Kaye. 1998. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur. J. Immunol. 28:669-680.
18. Gassim, S., A. M. El-Hassan, E. A. G. Khalil, A. Ismail, A. M. Y. Kadarn, A. Kharazmi, and T. G. Theander. 1998. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis Clin. Exp. Immunol. 111:64-69.
19. Ghalib, H. W., M. R. Piuvezam, YA. W. Skeily, M. Siddig, F. A. Hasim, A. M. El-Hassan, D. M. Russo, and S. G. Reed. 1993. Interleukin-10 production correlates with pathology in human Leishmania donovani infection. J. Clin. Investig. 92:324-329.
20. Groux, H., F. Cottrez, M. Rouleau, S. Mauze, S. Aantonenko, S. Hurst, T. McNeil, M. Bigler, M-G. Roncarolo, and R. L. Coffman. 1999. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigenpresenting cells. J. Immunol. 62:1723-1729.
21. Kane, M. M., and D. M. Mosser. 2001. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166:1141-1147.
22. Karp, C. L., S. H. El-Safi, T. A. Wynn, M. M. H. Satti, A. N. Kordofani, F. A. Hashim, M. Hag-Ali, F. A. Neva, T. B. Nutman, and D. L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Investig. 91:1644-1648.
23. Kenney, R. T., D. L. Sacks, A. A. Gam, H. W. Murray, and S. Sundar. 1998. Splenic cytokine responses in Indian kala-azar before and after treatment. Clin. Infect. Dis. 27:215-219.
24. Kuhn, R., J. Lohler, R. Rennick, K. Rajewsky, and W. Muller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263-274.
25. Laochumroonvorapong, P., J. Wang, C.-C. Liu, W. Ye, A. L. Moreira, K. B. Elkon, V. H. Freedman, and G. Kaplan. 1997. Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of mycobacterial infection in mice. Infect. Immun. 65:127-132.
26. McElrath, J. J., H. W. Murray, and Z. A. Cohn. 1988. The dynamics of granuloma formation in experimental visceral leishmaniasis. J. Exp. Med. 167:1927-1937.
27. Melby, P. C., Y-Z. Yang, J. Cheng, and W. Zhao. 1998. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect. Immun. 66:18-27.
28. Melby, P. C., V. V. Tyron, B. Chandrasekar, and G. L. Freeman. 1998. Cloning of Syrian hamster (Merocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect. Immun. 66:2135-2142.
29. Miralles, G. D., M. Y. Stoeckle, D. F. McDermott, F. D. Finkelman, and H. W. Murray. 1994, Induction of Thl and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 62:1058-1063.
30. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765.
31. Murphy, M. L., U. Wille, E. N. Villegas C. A. Hunter, and J. P. Farrell. 2001. IL-10 mediates suscpetibility to Leishmania donovani infection. Eur. J. Immunol. 31:2848-2856.
32. Murray, H. W. 2000. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int. J. Infect. Dis. 4:158-177.
33. Murray, H. W. 2001. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. 45:2185-2197.
34. Murray, H. W., G. D. Miralles, M. Y. Stoeckle, and D. F. McDermott. 1993. Role and effect of interleukin-2 in experimental visceral leishmaniasis. J. Immunol. 151:929-934.
35. Murray, H. W., J. Cervia, J. Hariprashad, A. P. Taylor, M. Y. Stoeckle, and H. Hockman. 1995. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J. Clin. Investig. 95:1183-1189.
36. Murray, H. W., C. Montelibano, R. Peterson, and J. P. Sypek. 2000. Interleukin 12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 182:1497-1502.
37. Murray, H. W. 2001. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int. J. Exp. Pathol. 82:249-276.
38. Murray, H. W. 1999. Granulomatous inflammation: host antimicrobial defense in the tissues in visceral leishmaniasis, p. 977-994. In J. Gallin, R. Synderman, D. Fearon, B. Haynes, and C. Nathan (ed.), Inflammation: basic principles and clinical correlates, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
39. Murray, H. W., and S. Delph-Etienne. 2000. Role of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 68:288-293.
40. Murray, H. W., A. Jungbluth, E. Ritter, C. Montelibano, and M. W. Marino. 2000. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun. 68:6289-6293.
41. Murray, H. W., M. J. Oca, A. M. Granger, and R. D. Schreiber. 1989. Successful response to chemotherapy in experimental visceral leishmaniasis: requirement for T cells and effect of lymphokines. J. Clin. Investig. 83:1254-1259.
42. Murray, H. W., J. D. Berman, and S. D. Wright. 1988. Immunochemotherapy for intracellular Leishmania donovani infection: interferon-gamma plus pentavalent antimony. J. Infect. Dis. 157:973-978.
43. Murray, H. W., J. Hariprashad, and R. L. Coffman. 1997. Behavior of visceral Leishmania donovani in an experimentally induced Th2 cell-associated response model. J. Exp. Med. 185:867-874.
44. Murray, H. W., and C. F. Nathan. 1999. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189:741-746.
45. Murray, H. W. 2000. Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation. Infect. Immun. 68:6294-6299.
46. Murray, P. J., L. Wang, C. Onufryk, R. I., Tepper, and R. A. Young. 1997. T-cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J. Immunol. 158:315-321.
47. Nabors, G. S. 1997. Modulating ongoing Th2-cell responses in experimental leishmaniasis. Parasitol. Today 13:76-79.
48. Powrie, F., S. Menon, and R. L. Coffman. 1993. IL-4 and IL-10 synergize to inhibit cell-mediated immunity in vivo. Eur. J. Immunol. 23:2223-2229.
49. Quinnell, R. J., O. Courtenay, M-A. Shaw, M. J. day, L. M. Garcez, C. Dye, and P. M. Kaye. 2001. Tissue cytokine responses in canine visceral leishmaniasis. J. Infect. Dis. 183:1421-1424.
50. Sang, D. K., J. H. Ouma, C. C. John, C. C. Whalen, C. L. King, A. A. Mahmoud, and F. P. Heinzel. 1999. Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. J. Infect. Dis. 179:743-746.
51. Satoskar, A. R., S. Rodig, S. R. Telford, A. A. Satoskar, S. K. Ghosh, F. von Lichtenberg, and J. R. David. 2000. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic pathology. Eur. J. Immunol. 30:834-839.
52. Satoskar, A., H. Bluethmann, and J. Alexander. 1995. Disruption of the murine interleukin-4 gene inhibits disease progession during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63:4894-4899.
53. Sewnath, M. E., D. P. Olszyna, R. Birjmohun, F. J. W. ten Kate, D. J. Gouma, and T. van der Poll. 2001. IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J. Immunol. 166:6323-6331.
54. Sundar, S., and H. W. Murray. 1997. Response to interferony plus antimony in Indian visceral leishmaniasis. J. Infect. Dis. 176:1117-1121.
55. Sundar, S., and H. W. Murray. 1995. Effect of treatment with interferongamma alone in Indian visceral leishmaniasis. J. Infect. Dis. 172:1627-1629.
56. Sundar, S., S. G. Reed, S. Sharma, A. Mehrota, and H. W. Murray. 1997. Circulating Thl cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trop. Med. Hyg. 56:522-526.
57. Taylor, A., and H. W. Murray. 1997. Intracellular antimicrobial activity in the absence of interferon-υ: effect of interleukin 12 in experimental visceral leishmanaisis in interferon-υ gene-disrupted mice. J. Exp. Med. 185:1231-1239.
58. Tumang, M., C. Keogh, L. L. Moldawer, R. Teitelbaum, J. Hariprashad, and H. W. Murray. 1994. The role and effect of tumor necrosis factor-alpha in experimental visceral leishmaniasis. J. Immunol. 153:768-775.
59. Wilson, M. E., M. Sandor, A. M. Blum, B. M. Young, A. Metwali, D. Elliott, R. G. Lynch, and J. V. Weinstick. 1996. Local suppression of IFN-υ in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J. Immunol. 156:2231-2239.
60. Wilson, M. E., B. M. Young, B. L. Davidson, K. A. Mente, and S. E. McGowan. 1998. The importance of transforming growth factor beta-β in murine visceral leishmaniasis. J. Immunol. 161:6148-6155.